Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer.

ABSTRACT: Hepatocellular carcinoma (HCC) is a prevalent cancer with limited effective treatments. Eribulin mesylate is a novel chemotherapy drug that inhibits microtubule elongation and may impact the tumor microenvironment and immune pathway. This study aims to investigate the impact of changes in microtubule acetylation levels on HCC development and treatment outcomes. Clinical and molecular data were aggregated from databases, with survival analysis conducted to evaluate the relevance of microtubule acetylation. In vitro experiments using HCC cell lines and a tumor cell transplantation model in C57BL/c mice were performed to investigate the effects of microtubule acetylation on Eribulin treatment. A significant correlation was found between the level of lysine 40 acetylation of α-tubulin (

SUBMITTER: Zhong Y 

PROVIDER: S-EPMC10695797 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature